SUPERNUS PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SUPERNUS PHARMACEUTICALS, INC. | ||
| By: | /s/ JACK A. KHATTAR | |
| Name: | Jack A. Khattar | |
| Title: | President and Chief Executive Officer | |
Date: February 25, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and the dates indicated below:
| Signature | Title | Date |
|---|---|---|
| /s/ JACK A. KHATTAR | President and Chief Executive Officer and Director (Principal Executive Officer) | February 25, 2025 |
| /s/ TIMOTHY C. DEC | Senior Vice-President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | February 25, 2025 |
| /s/ CHARLES W. NEWHALL, III. | Director and Chairman of the Board | February 25, 2025 |
| /s/ CARROLEE BARLOW, M.D., PH.D. | Director | February 25, 2025 |
| /s/ GEORGES GEMAYEL, PH.D. | Director | February 25, 2025 |
| /s/ FREDERICK M. HUDSON | Director | February 25, 2025 |
| /s/ BETHANY SENSENIG | Director | February 25, 2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.